MIRA Pharmaceuticals (NASDAQ:MIRA) | WebDisclosure

Basculer en Français

11315	Companies
251418	Keywords
180508	Articles
137249	Press releases

Home
Companies
MIRA Pharmaceuticals

PRESS RELEASE

published on 08/19/2025 at 14:30, 1 year 2 months ago

MIRA Pharmaceuticals Announces Completion of Phase 1 Single Ascending Dose for Oral Ketamir-2 with No Safety Concerns, Advances to Multiple Ascending Dose Stage
MIRA Pharmaceuticals, Inc. announces successful completion of Phase 1 Single Ascending Dose trial for oral Ketamir-2, preparing for U.S. Phase 2a trial in Q4 2025

Clinical Trial Phase 1 MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain
BRIEF

published on 08/12/2025 at 14:35, 1 year 2 months ago

MIRA Pharmaceuticals développe le kétamir-2 pour le traitement de la douleur neuropathique

Essais Cliniques Croissance Du Marché Médicaments Ketamir-2 Douleur Neuropathique
BRIEF

published on 08/12/2025 at 14:35, 1 year 2 months ago

MIRA Pharmaceuticals Advances Ketamir-2 for Neuropathic Pain Treatment

Pharmaceuticals Clinical Trials Market Growth Ketamir-2 Neuropathic Pain
PRESS RELEASE

published on 08/12/2025 at 14:30, 1 year 2 months ago

MIRA Pharmaceuticals' Second Ketamir-2 Manuscript Accepted for Peer-Reviewed Publication Demonstrating Superior Efficacy in Preclinical Neuropathic Pain Models Versus Ketamine, Gabapentin, or Pregabalin
MIRA Pharmaceuticals announces the acceptance of a manuscript in Frontiers in Pharmacology detailing Ketamir-2's efficacy in neuropathic pain, supporting Phase 2a trials by 2025

Clinical Trials MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain Pharmacology
BRIEF

published on 07/30/2025 at 13:35, 1 year 3 months ago

Le kétamir-2 topique de MIRA Pharmaceuticals est comparable à la morphine injectée dans une étude sur la douleur

Soulagement De La Douleur Étude Préclinique Kétamir-2 Topique Comparaison De La Morphine Traitement Localisé
BRIEF

published on 07/30/2025 at 13:35, 1 year 3 months ago

MIRA Pharmaceuticals' Topical Ketamir-2 Matches Injected Morphine in Pain Study

Preclinical Study Pain Relief Topical Ketamir-2 Morphine Comparison Localized Treatment
PRESS RELEASE

published on 07/30/2025 at 13:30, 1 year 3 months ago

MIRA Pharmaceuticals Reports New Topical Ketamir-2 shows comparable effects to Injected Morphine in Preclinical Pain Study
MIRA Pharmaceuticals announces new preclinical data showing topical Ketamir-2 provides effective pain relief comparable to injected morphine in animal models. The treatment has potential for both centralized and localized pain pathways

Preclinical Data MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain Topical Pain Relief
BRIEF

published on 07/29/2025 at 13:35, 1 year 3 months ago

MIRA Pharmaceuticals reçoit le feu vert de la FDA pour les essais du kétamir-2

Autorisation De La FDA Expansion Stratégique Ketamir-2 Douleur Neuropathique Essai De Phase 1
BRIEF

published on 07/29/2025 at 13:35, 1 year 3 months ago

MIRA Pharmaceuticals Receives FDA Green Light for Ketamir-2 Trials

FDA Clearance Phase 1 Trial Strategic Expansion Ketamir-2 Neuropathic Pain
PRESS RELEASE

published on 07/29/2025 at 13:30, 1 year 3 months ago

MIRA Pharmaceuticals Announces FDA Clearance of IND for Ketamir-2, Enabling U.S. Clinical Trials in Neuropathic Pain
MIRA Pharmaceuticals advances non-opioid oral drug Ketamir-2 for neuropathic pain, clears FDA IND for Phase 2a, demonstrates potent effects in preclinical studies

FDA Preclinical Studies MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain

Accesswire

Published on 11/11/2026 at 03:30, 19 minutes ago

CoTec Holdings Corp. Files Third Quarter Financial Statements and MD&A and Provides Market Commentary
Published on 11/11/2026 at 00:40, 3 hours 9 minutes ago

Upgraded Tunkillia MRE Validates Optimised Scoping Study
Published on 11/10/2026 at 23:30, 4 hours 19 minutes ago

CCL Industries Announces 2026 Third Quarter Results
Published on 11/10/2026 at 23:00, 4 hours 49 minutes ago

Vanta Announces Appointment of Chief Financial Officer and Corporate Secretary
Published on 11/10/2026 at 23:00, 4 hours 49 minutes ago

Battery X Metals Announces Appointment of Chief Financial Officer and Corporate Secretary

View all ACCESSWIRE

EQS Group

Published on 11/11/2026 at 03:25, 24 minutes ago

Experts Gather in Nanjing to Explore the Cultural Heritage of the Yangtze River
Published on 11/11/2026 at 00:15, 3 hours 34 minutes ago

Lean Focus Launches Asia Pacific: Local Expertise. Global Impact.
Published on 11/10/2026 at 23:15, 4 hours 34 minutes ago

GSMA MWC26 Doha welcomed over 10,000 attendees, as world-first ITU co-location puts MENA at the centre of global connectivity policy and innovation
Published on 11/10/2026 at 21:24, 6 hours 24 minutes ago

EQS-Adhoc: Kapsch TrafficCom AG:
Published on 11/10/2026 at 21:18, 6 hours 31 minutes ago

ARYZTA director steps down

Les Echos

Published on 11/10/2026 at 18:00, 9 hours 49 minutes ago

Déclaration du nombre total des droits de vote et du nombre d’actions au 31 octobre 2026
Published on 11/10/2026 at 17:45, 10 hours 4 minutes ago

Damartex / Descriptif du programme de rachat d'actions
Published on 11/10/2026 at 17:40, 10 hours 9 minutes ago

Production du 3ième trimestre 2026
Published on 11/10/2026 at 17:35, 10 hours 14 minutes ago

ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 octobre 2026
Published on 11/10/2026 at 17:31, 10 hours 17 minutes ago

CNP Assurances SA annonce le succès de l’émission d’une obligation subordonnée Tier 2 de 500 M€.

View all LES ECHOS COMFI WIRE